重组MUC1-MBP融合蛋白联合R848对小鼠T细胞免疫活性的诱导作用

doi:10.13481/j.1671-587x.20170309

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (03): 507-511.doi: 10.13481/j.1671-587x.20170309

重组MUC1-MBP融合蛋白联合R848对小鼠T细胞免疫活性的诱导作用

孙敏英¹, 刘果木², 接晶², 谢飞², 翟瑞萍², 陈潭秀², 袁红艳², 台桂香²

1. 吉林大学基础医学院医学生物学实验中心, 吉林长春 130021;
2. 吉林大学基础医学院免疫学教研室, 吉林长春 130021

收稿日期:2016-09-19 出版日期:2017-05-28 发布日期:2017-06-01
通讯作者: 台桂香,教授,博士研究生导师(Tel:0431-85619476,E-mail:taiguixiang@163.com) E-mail:taiguixiang@163.com
作者简介:孙敏英(1987-),女,吉林省长春市人,助理工程师,理学硕士,主要从事医学生物学方面的研究。
基金资助:
吉林省科技厅科技攻关双十工程项目资助课题（20140201012YY）；吉林省长春市科技局科技项目资助课题（201622010100025）

Inductive effect of recombinant MUC1-MBP fusion protein combined with R848 on immune activity of T cells in mice

SUN Minying¹, LIU Guomu², JIE Jing², XIE Fei², ZHAI Ruiping², CHEN Tanxiu², YUAN Hongyan², TAI Guixiang²

1. Experimental Center of Medical Biology, School of Basic Medical Sciences, Jilin University, Changchun 130021, China;
2. Department of Immunology, School of Basic Medical Sciences, Jilin University, Changchun 130021, China

Received:2016-09-19 Online:2017-05-28 Published:2017-06-01

摘要/Abstract

摘要： 目的：研究MUC1-MBP联合TLR7/8激动剂R848对小鼠T细胞免疫活性的诱导作用，为寻找重组MUC1-MBP融合蛋白的合适佐剂提供实验依据。方法：21只C57BL/6小鼠随机分为对照组（注射生理盐水）、MUC1-MBP+ R848组（注射MUC1-MBP+ R848）和MUC1-MBP+卡介苗（BCG）组（注射MUC1-MBP+ BCG），每组7只。第2次免疫后第4~7天无菌取脾脏组织，测定脾指数；淋巴细胞增殖反应测定各组小鼠的刺激指数（SI）；ELISA法测定小鼠脾细胞培养上清中肿瘤坏死因子γ（TNF-γ）和白细胞介素4（IL-4）水平；流式细胞术检测小鼠脾细胞中T淋巴细胞亚群比例。结果：与对照组比较，MUC1-MBP+R848组和MUC1-MBP+BCG组小鼠脾指数均升高（P<0.01），SI升高（P<0.05），TNF-γ水平升高（P<0.05或P<0.01）；且MUC1-MBP+R848组小鼠上述指标高于MUC1-MBP+BCG组（P<0.05或P<0.01）；IL-4水平略微升高，但差异无统计学意义（P>0.05）。与对照组比较，MUC1-MBP+ R848组和MUC1-MBP+ BCG小鼠脾细胞中CD3⁺细胞、CD4⁺细胞和CD8⁺细胞比例明显升高（P<0.05或P<0.01）。结论：MUC1-MBP 融合蛋白联合R848或BCG均能诱导小鼠倾向于Th1的细胞免疫应答反应，R848是良好的MUC1-MBP候选佐剂分子。

关键词: R848, 肿瘤疫苗, 佐剂, MUC1-MBP

Abstract: Objective: To study the inductive effect of recombinant MUC1-MBP fusion protein combined with R848 on the immune activity of T cells in the mice,and to provide experimental basis for searching the suitable adjuvants of recombinant MUC1-MBP fusion protein. Methods: A total of 21 C57BL/6 mice were randomly divided into control group(treat with normal saline),MUC1-MBP+R848 group (treated with MUC1-MBP+R848),and MUC1-MBP+baillus calmette guerin(BCG) group(treated with MUC1-MBP+BCG)(n=7).After immunized for 4-7 d,the spleen tissue was taken and the spleen indexes of the mice in various groups were measured; the stimmulus index(SI) of the mice was detected by lymphocyte proliferation response;the levels of tumor necrosis factor-γ(TNF-γ) and interleukin-4(IL-4) were detected by ELISA method;the proprotions of T lymphocyte subsets in spleen cells were analyzed by flow cytometry. Results: Compared with control group,the spleen indexes,SI,and TNF-γ levels of the mice in MUC1-MBP+ R848 and MUC1-MBP+BCG groups were significantly increased (P<0.05 or P<0.01);the indexes metioned above of the mice in MUC1-MBP+ R848 were higher than those in MUC1-MBP+BCG group;the IL-4 levels had no significant difference(P>0.05).Compared with control group,the proprotions of CD3⁺T,CD4⁺T,and CD8⁺ T cells of the mice in MUC1-MBP+ R848 group and MUC1-MBP+BCG group were significantly increased(P<0.05 or P<0.01). Conclusion: Both MUC1-MBP fusion protein combined with R848 and BCG can induce the Th1 type of immune activity in the mice,and R848 is the potential candidate adjuvant for MUC1-MBP.

Key words: R848, MUC1-MBP, adjuvant, cancer vaccine

中图分类号:

Q816

孙敏英, 刘果木, 接晶, 谢飞, 翟瑞萍, 陈潭秀, 袁红艳, 台桂香. 重组MUC1-MBP融合蛋白联合R848对小鼠T细胞免疫活性的诱导作用[J]. 吉林大学学报(医学版), 2017, 43(03): 507-511.

SUN Minying, LIU Guomu, JIE Jing, XIE Fei, ZHAI Ruiping, CHEN Tanxiu, YUAN Hongyan, TAI Guixiang. Inductive effect of recombinant MUC1-MBP fusion protein combined with R848 on immune activity of T cells in mice[J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 507-511.

参考文献

[1] Acres B,Limacher JM.MUC1 as a target antigen for cancer immunotherapy[J]. Expert Rev Vaccines,2005,4(4):493-502.
[2] Nath S,Mukherjee P. MUC1:a multifaceted oncoprotein with a key role in cancer progression[J].Trends Mol Med,2014,20(6):332-342.
[3] Vassilaros S,Tsibanis A,Tsikkinis A,et al.Up to 15-year clinical follow-up of a pilot phase Ⅲ immunotherapy study in stage Ⅱ breast cancer patients using oxidized mannan-MUC1[J].Immunotherapy,2013,5(11):1177-1182.
[4] Quoix E,Ramlau R,Westeel V,et al.Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer:a controlled phase 2B trial[J].Lancet Oncol,2011,12(12):1125-1133.
[5] Wurz GT,Kao CJ,Wolf M,et al.Tecemotide:An antigen-specific human vaccines &immunotherapeutics[J].Cancer Immunother,201410(11):3383-3393.
[6] Fang F,Ma J,Ni W,et al.MUC1 and maltose-binding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice[J].Mol Med Rep,2014,7(10):1056-1064.
[7] Hu B,Wang J,Guo Y,et al.Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine[J].Int Immunopharmacol,2016,33:108-118.
[8] Wille-Reece U,Flynn BJ,Loré K,et al.Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates[J].J Exp Med,2006,203(5):1249-1258.
[9] Steinhagen F,Kinjo T,Bode C,et al.TLR-based immune adjuvants[J].Vaccine,2011,29(17):3341-3355.
[10] Girart MV,Fuertes MB,Domaica CI,et al.Engagement of TLR3,TLR7,and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12[J].J Immunol,2007,179(6):3472-3479.
[11] 方芳.重组MUC1-MBP融合蛋白疫苗抗肿瘤作用机制研究[D].长春:吉林大学,2010.
[12] 孙霞霞.不同佐剂对重组MUC1-MBP融合蛋白诱导的免疫活性的影响[D].长春:吉林大学,2013.
[13] Fujita Y,Hirai K,Nishida K,et al.6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine:Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine[J].Amino Acids,2016,48(5):1319-1329.
[14] Smith AJ,Li Y,Bazin HG,et al.Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants[J].Vaccine,2016,34(36):4304-4312.
[15] Wang Y,Chen K,Wu Z,et al.Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice[J].Int J Infect Dis,2014,12(29):31-36.
[16] 尹凌凡,范艳莹,李丽,等.Toll样配体(R-848)与IL-12对人NK细胞亚群IFN-γ产生的作用[J].细胞与分子免疫学杂志,2007,23(7):623-626.
[17] 范艳莹,付笑迎,尹凌凡,等.TLR7/8配体(R848)对人NK细胞杀伤功能的作用及其机制的探讨[J].免疫学杂志,2010,26(8):657-660.

重组MUC1-MBP融合蛋白联合R848对小鼠T细胞免疫活性的诱导作用

Inductive effect of recombinant MUC1-MBP fusion protein combined with R848 on immune activity of T cells in mice

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

Metrics

本文评价

推荐阅读 0

[1]	孙敏英, 周红月, 接晶, 谢飞, 翟瑞萍, 陈潭秀, 袁红艳, 台桂香. 胸腺肽α1诱导MUC1特异性Th2型免疫应答[J]. 吉林大学学报(医学版), 2018, 44(02): 299-304.
[2]	王娟，谢飞，陈潭琇，孙霞霞，李琼书，台桂香. 超滤技术去除重组MUC1-MBP融合蛋白中内毒素的效果评价[J]. 吉林大学学报(医学版), 2014, 40(03): 539-542.
[3]	段秀梅\|邹亚斌\|马洪喜\|李树蕾\|王银萍\|王超\|李玉琴. 结核杆菌热休克蛋白70刺激表位在融合基因疫苗中的佐剂作用[J]. J4, 2012, 38(3): 506-511.
[4]	李贺, 王华, 吴秀丽, 卫红飞, 孙陆果, 张永胜, 于永利, 王丽颖, 万敏. 卡介苗热休克蛋白70对肿瘤细胞裂解物免疫原性的影响[J]. J4, 2011, 37(1): 68-71.
[5]	方芳, 宋献美, 张庆勇, 马吉春, 窦蕊, 陈文博, 台桂香. 人MUC1和鼠Muc1蛋白疫苗抗肿瘤作用的比较[J]. J4, 2010, 36(1): 114-118.
[6]	陈亚静，吴秀丽，王丽，卫红飞，王丽颖，于永利 . 热休克蛋白融合蛋白抗肿瘤免疫佐剂的初步筛选[J]. J4, 2007, 33(4): 642-646.
[7]	时阳，谭岩，刘力华，太京华，方艳秋，段秀梅，姜艳芳，许淑芬. 小鼠白细胞介素18真核表达质粒的构建及基因多态性分析[J]. J4, 2004, 30(2): 206-208.